The estimated Net Worth of Quoc Le Nguyen is at least $2.01 Milion dollars as of 9 May 2023. Mr. Nguyen owns over 79,571 units of 89bio Inc stock worth over $1,448,884 and over the last 5 years he sold ETNB stock worth over $0. In addition, he makes $557,849 as Chief Technical Operations Officer and Head of Quality at 89bio Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Nguyen ETNB stock SEC Form 4 insiders trading
Quoc has made over 2 trades of the 89bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 79,571 units of ETNB stock worth $247,466 on 9 May 2023.
The largest trade he's ever made was exercising 79,571 units of 89bio Inc stock on 9 May 2023 worth over $247,466. On average, Quoc trades about 3,824 units every 41 days since 2020. As of 9 May 2023 he still owns at least 178,654 units of 89bio Inc stock.
You can see the complete history of Mr. Nguyen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Quoc Le-Nguyen biography
Quoc Le-Nguyen serves as Chief Technical Operations Officer and Head of Quality of the Company. Mr. Le-Nguyen was Senior Vice President, Global Head of Technical Operations & Quality for Aduro BioTech, Inc., a biotechnology company, from September 2015 to July 2018, where he was responsible for clinical supply including analytical and process development, manufacturing, supply chain and quality for cell therapy, small molecule and antibody platforms. Prior to Aduro, Mr. Le-Nguyen was the Vice President of Manufacturing Operations for Bayer AG from September 2007 to September 2013, where he was responsible for the Betaferon/Betaseron franchise. Prior to Bayer, Mr. Le-Nguyen worked in biologics manufacturing for Novartis International AG, Chiron Corporation and BioMarin Pharmaceutical Inc.
What is the salary of Quoc Nguyen?
As the Chief Technical Operations Officer and Head of Quality of 89bio Inc, the total compensation of Quoc Nguyen at 89bio Inc is $557,849. There are 5 executives at 89bio Inc getting paid more, with Rohan Palekar having the highest compensation of $1,022,610.
How old is Quoc Nguyen?
Quoc Nguyen is 52, he's been the Chief Technical Operations Officer and Head of Quality of 89bio Inc since 2019. There are 11 older and 4 younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.
What's Quoc Nguyen's mailing address?
Quoc's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.
Insiders trading at 89bio Inc
Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... oraz Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.
What does 89bio Inc do?
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
What does 89bio Inc's logo look like?
Complete history of Mr. Nguyen stock trades at 89bio Inc
89bio Inc executives and stock owners
89bio Inc executives and other stock owners filed with the SEC include:
-
Rohan Palekar,
Chief Executive Officer, Director -
Rohan Palekar,
CEO & Director -
Hank Mansbach,
Chief Medical Officer -
Dr. Harry Mansbach M.D.,
Chief Medical Officer -
Dr. Hank Mansbach M.D.,
Chief Medical Officer -
Quoc Le-Nguyen,
Chief Technical Operations Officer and Head of Quality -
Quoc Le-Nguyen,
Chief Technical Operations Officer & Head of Quality -
Ram Waisbourd,
Chief Operating Officer and Chief Business Officer -
Michael Hayden,
Independent Director -
Anat Naschitz,
Independent Director -
Gregory Grunberg,
Independent Director -
Derek DiRocco,
Independent Director -
Ryan Martins,
Chief Financial Officer -
Steven Altschuler,
Independent Chairman of the Board of Director -
Yun Bai,
VP & Head of CMC -
Amanda Hill,
VP of People & Culture -
Melissa Abel,
VP of Commercial Strategy & Communication -
Shiva K. Natarajan,
VP of Fin. & Principal Accounting Officer -
Ram Waisbourd,
COO & Chief Bus. Officer -
Ryan Stephen Martins,
Chief Financial Officer -
Charles Mc Wherter,
-
Tomer Pontifax (Israel) V, ...,
-
Capital Management, L.P.Ra ...,
-
Advisors Llc Orbi Med Capit...,
-
Capital Partners Iii, Llc L...,
-
Kathleen Laporte,
-
Edward Morrow Iii Atkinson,
-
Capital Management, L.P.Ra ...,
-
Harry H Mansbach,
Chief Medical Officer -
Lota S. Zoth,
-
Martin Babler,
-
Francis Willard Sarena,
Chief Operating Officer